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Abstract
Allograft coronary disease is the dominant cause of increased risk of death after cardiac transplantation. While the
percutaneous insertion of stents is the most efficacious revascularization strategy for allograft coronary disease there is a
high incidence of stent renarrowing. We developed a novel rabbit model of sex-mismatched allograft vascular disease as
well as the response to stent implantation. In situ hybridization for the Y-chromosome was employed to detect male cells in
the neointima of stented allograft, and the population of recipient derived neointimal cells was measured by quantitative
polymerase chain reaction and characterized by immunohistochemistry. To demonstrate the participation of circulatory
derived cells in stent neointima formation we infused ex vivo labeled peripheral blood mononuclear cells into native rabbit
carotid arteries immediately after stenting. Fourteen days after stenting the neointima area was 58% greater in the stented
vs. non-stented allograft segments (p=0.02). Male cells were detected in the neointima of stented female-to-male allografts.
Recipient-derived cells constituted 72.165.7% and 81.564.2% of neointimal cell population in the non-stented and stented
segments, respectively and the corresponding proliferation rates were only 2.760.5% and 2.360.2%. Some of the recipient-
derived neointimal cells were of endothelial lineage. The ex vivo tagged cells constituted 9.060.4% of the cells per high
power field in the stent neointima 14 days after stenting. These experiments provide important quantitative data regarding
the degree to which host-derived blood-borne cells contribute to neointima formation in allograft vasculopathy and the
early response to stent implantation.
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Introduction
The artery wall consists of three layers: the (inner) intima, the
media and the (outer) adventitia. Non-diseased human coronary
arteries normally have a modest layer of intimal thickening (or
neointima, NI) that consists of an accumulation of smooth muscle
cells (SMCs) and extracellular matrix[1]. Currently, it is believed
that medial SMC proliferation and inward migration, as well as
the transmigration and retention of blood borne inflammatory
cells play key roles in transforming a benign NI into the obstructive
lesions that are seen in atherosclerotic coronary artery disease
(CAD), as well as allograft coronary disease (ACD) that occurs
after heart transplantation[2,3]. Like garden variety CAD, ACD
can ultimately lead to life threatening clinical sequelae, and the
most common revascularization strategy for either of these entities
involves the insertion of metallic scaffolding devices known as
stents. While stent renarrowing due to recurrent NI formation
(also know as in-stent restenosis or ISR) occurs in up to 5-30% of
CAD lesions (depending on the stent and/or drug coating on the
stent)[4,5], ISR is a more frequent and serious problem for ACD
lesions[3,6–9]. For example, Simpson and colleagues report 6 and
12 month ISR rates of 41% and 53%; respectively, with 39% of
stented patients dying or undergoing repeat cardiac transplanta-
tion within approximately 2 years of their first intervention[9].
The histopathology of ACD is characterized by inflammatory cell
infiltrates with SMC accumulation and hence is more akin to ISR
than the complex atherosclerotic lesions. Indeed, Jonas and
colleagues recently demonstrated that angiographic progression
of ACD and ISR lesions in allograft coronary arteries correlate
and share histological features[3].
The pathogenesis of ACD is incompletely understood, and
debate lingers over the relative importance of immune vs. non-
immune factors, as well as the origin of NI cells. Unfortunately,
experimental studies involving a variety of animal models of
transplantation have produced discordant results (see review by
Hillebrands et al.[10]). Indeed, there is critical concern when high-
resolution confocal or deconvolution microscopy is not used to
track cell lineage in allografts (see editorial by Hoofnagle et al.[11]).
Regardless of these experimental studies, one cannot ignore
observations from a handful of important human studies that
suggest that host cells participate in allograft disease. For example,
in 1971 Kennedy and Weissman[12] used anti-sera directed
against donor and host HL-A antigens to suggest host cells were at
least partially responsible for NI formation in a human cardiac
allograft coronary artery. Together with at least five larger and
more sophisticated studies of human transplantation, there is
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non-diseased or diseased arteries of allografts[13–17].
Hence, whilethere is information available about the involvement
of host-derived cells in allograft NI formation, many questions
remain. For example, the precise degree to which host cells populate
the allograft NI has only been assessed semi-quantitatively by
sampling a relatively small number of cells in just a handful of
arteries. Certainly, a more comprehensive quantitative assessment of
the degree to which blood borne host cells participate in NI
formation is required before we can assign a level of significance to
these cells in the pathogenesis of allograft vascular disease, and
determine the need to develop therapeutic strategies to inhibit their
participation.Therefore, the goals of the current study are to address
thefollowingquestionsusingarabbitmodelofallograftvasculopathy
and the responsetostent implantation:i)whatisthe originofNIcells
in allografts with or without stents? ii) to what (precise) degree do
recipient cells contribute to the NI formation? and iii) what is the
identity of the NI cells that populate the allograft NI?
Results
Model of Allograft Vascular Disease and Stent NI
Formation
New Zealand White (NZW) rabbits were used for these
experiments because their carotid artery is similar in calibre to
human coronary arteries and hence suitable for both surgical
transplantation and stent deployment. Allografting of a female
carotid artery to a male recipient (n=6), and vice versa (n=6), was
performed (Figure 1A–F, Movie S1 and S2 available online).
Two weeks after stent deployment rabbits were euthanized and
vascular tissues were harvested for analyses. Total plasma
cholesterol levels increased almost fourfold after 5 weeks of
ingesting a cholesterol-enriched diet (e.g., baseline: 56.762.0 mg/
dL and at euthanasia: 200.2613.2 mg/dL).
Immunocytochemical and Histomorphological
Characterization of NI
A modest NI was present in all non-stented and stented
allografts segments as well as stented native carotid arteries
(Figure 2A & B). In non-stented native carotid arteries a NI was
absent (data not shown). In non-stented allograft segments the NI
largely consisted of an almost equal mix of SMCs and
macrophages (Figure 2C). As well, a minor infiltration of
lymphocytes was present in the allograft NI-consistent with
previous descriptions of the early NI phase of ACD[10]. The
allograft stent NI was distinct from non-stented allograft segments
as well as the stent NI of native carotid arteries. Specifically, in the
stent NI of 7/12 allografts more than 50% of the cells failed to
label with SMC, macrophage or lymphocyte markers. In the NI of
Figure 1. Sex-mismatched rabbit common carotid allograft model. (A–C) Donor carotid artery acting as an allograft to the recipient’s
common carotid artery. Titanium clips were used to ligate recipient artery. After transplantation the recipient carotid was cut in the middle and the
cerebral circulation was restored in the allograft. Three weeks later, a S670 stent (3.0 diameter612 mm length) was deployed in the middle of the
allograft. (D) Photo of microsurgery showing the bypass allograft anastomosed to native common carotid. (E) Angiogram of the allograft after stent
implantation. (F) Patent allograft (without contrast dye) showing the radiopaque stent located in the middle of the graft. A stent is also present in the
contralateral native carotid artery.
doi:10.1371/journal.pone.0001894.g001
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phages and 1 by SMCs. In contrast, the NI of stented native
arteries largely consisted of SMCs with macrophages that were
confined to the peri-strut tissue-consistent with our previous
description of stent NI formation in native rabbit carotid
arteries[18]. Griffonia Simplicifolia Lectin I-isolectin B4 (GSL I-
B4) was used to identify cells of endothelial lineage as it is well
recognized as a reliable endothelial marker[19,20]. As expected,
the luminal endothelium of non-stented allograft segments was
intact and immunolabeled for the endothelial marker GSL I-B4
(Figure 2D). However, we were surprised to find scattered within
the NI of the non-stented and stented allograft segments, as well as
stented native arteries multiple cells that were immunopositive for
this endothelial marker–yet did not appear to be part of vasa
vasorum (i.e., no organized cellular network encompassing red
blood cells).
While a modest NI formed in the allografts NI area varied
according to the location within the allograft (Figure 3A). At the
allograft anastomotic sites (the ends of the allograft that were
sutured to the carotid artery) the NI area was 59% larger than in
the non-stented body of the allograft (1.0560.13 mm
2 vs.
0.6660.07 mm
2, respectively, p,0.05). Interestingly, the area of
the NI at the site of stent implantation was 1.0460.14 mm
2 and
approximately 58% larger than the adjacent non-stented allograft
segment (p,0.05). In contrast, the NI generated in response to
stenting the contralateral (native) carotid artery was
Figure 2. Morphologic and immunohistochemical study of allograft, stented allograft and native artery. A & B: H&E stained tissue
section shown at 620–40 (top row) and 6200 (second row) magnifications with * denoting location of stent struts removed post-mortem. C: Dual
labeling for the macrophage marker RAM-11 (brown) and the SMC marker a-SMA (blue) demonstrates similar basal NI location of macrophages with
overlying SMCs. Note that larger allograft stent NI has a large number of cells that do not label with either of these cell markers. D: Labeling for the
endothelial specific marker GSL I-B4 (brown) shows immunopositive cells within the NI, particularly in the stent NIs of the allograft and native artery.
Orange arrow heads delineate the internal elastic lamina.
doi:10.1371/journal.pone.0001894.g002
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2 or only 54% of the allograft stent NI area
(p,0.01) and similar in magnitude to the non-stented allograft NI
found at a distance from anastomotic sites.
As a separate control for this allograft model, we studied a
cohort of three rabbits that underwent sex-mismatched carotid
artery transplantation but were euthanized 3-weeks post-trans-
plantation (i.e., without stent insertion). A NI was present in all
three 3 week old allografts, but was much smaller than that of the
5 week old stented allografts (0.08760.017 mm
2 vs.
1.0460.14 mm
2,p ,0.01). The NI cells of the 3 week old
allografts consisted mainly of SMCs and macrophages.
To determine the role of proliferation in the NI BrdU
immunolabeling was performed (Figure 3B). In the non-stented
(n=10) and stented (n=9) allograft segments the prevalence of
proliferating cells was low (2.760.5% and 2.360.2%; respective-
ly). The proliferation profile at the anastomoses (4.660.3%,
n=10) was higher than that of the non-stented and stented
allograft sites (p=0.002 and p,0.001; respectively). In the native
carotid artery (no stent) proliferation was virtually absent, but at
the site of stent insertion 1.660.3% of cells were proliferating–a
frequency similar to that found in non-stented or stented allografts
and certainly lower than that detected at the allograft anastomoses
(p,0.001).
Origin of Stent NI Cells
To assess the contribution of the recipient’s cells to stent NI
formation we employed two techniques. First, by using Fluorescent
in situ hybridization (FISH) for the Y chromosome male recipient
cells were detected in the NI of the non-stented segment of a
female-to-male allograft (Figure 4A), the NI in the allograft stent
(Figure 4B), and in the media of the proximal native artery
(Figure 4C). Similar to other reports[17,21] the sensitivity of
FISH to detect male cells was limited (e.g., we detected only
20.062.6% of positive cells in pure male tissue)–despite adequate
hybridization as reflected by parallel use of a control probe specific
for histone-H3 (data not shown).
Second, Laser capture microdissected (LCM) was used to
precisely isolate stent NI tissue (Figure 4D) and quantitative
polymerase chain reaction (Q-PCR) assessment of Y chromosome
copy number relative to that of an autosomal gene was employed
to determine the percentage of host or donor cells involved in NI
formation. The NIs ranged in area from approximately 0.48–1.48
mm
2, and had an average cell density of 6,085 cells/mm
2; hence
between 2,434 and 9,005 cells were sampled on each tissue slide
using LCM. Figure 4E shows the linearity of a sample standard
curve for GAPDH. Both the sex-determining region Y (SRY) and
GAPDH reactions were linear over a one million fold range for the
concentration of the standard plasmid. Furthermore, the correla-
tion coefficient for SRY and GAPDH were excellent (r
2 value
range: 0.99–1.00 and 0.98–1.00; respectively). Hence, using this
technique and the appropriate calculations we were able to
determine the origin of cells in the NI of both male and female
arteries. Examination of nine native carotid artery samples (5
female and 4 male) revealed that 96.566.6% of the cells were of
recipient origin (Figure 4F). The contribution of recipient cells to
the allograft NI in non-stented segments (n=9) was 72.165.7% of
cells. In the larger NI of the allograft stents (n=10) 81.564.2% of
the cells were of recipient origin. Therefore, by inference
approximately 27.9% of the non-stented allograft NI cells
originated from the allograft, while only 18.5% of the stent NI
cells in the allografts were derived from the vessel wall. Given the
relatively low proliferation profile in the allograft NI, these data
suggest that host cell engraftment plays a major role in allograft NI
formation.
Differentiation of Circulatory Cells: In Vitro and In Vivo
To test whether the GSL I-B4 immunopositive NI cells
(described above) may be host-derived cells that differentiate
from an endothelial to a SMC or monocyte/macrophage lineage
we cultured rabbit peripheral blood mononuclear cells (PBMCs)
on fibronectin-coated plates in EGM-2 media. Similar to human
PBMCs maintained in culture for seven days[22] the adherent
rabbit PBMCs on day 7 in culture were positive for both DiI-
acLDL uptake and GSL I-B4 labeling but negative for both a-
smooth muscle actin (SMA) and RAM-11 immunolabeling
(Figure 5A). However after 28 days the majority of cells
expressed a-SMA or RAM-11 but did not show DiI-acLDL
uptake or GSL I-B4 immunolabeling (Figure 5B). Hence, these
in vitro data suggest that PBMCs are capable of transdifferentiat-
ing from an EC lineage to either SMCs or monocyte/
macrophages.
Similarly, to directly determine if circulatory cells engraft stent
NI, rabbit PBMCs tagged ex-vivo with the fluorescent dye PKH26
(Figure 6A) were selectively injected into native carotid arteries
immediately after stent implantation. Fourteen days after stent
implantation PKH26-tagged cells constituted 9.060.4% of stent
NI cells per high power field (HPF) (Figure 6B–D).
Figure 3. Characterization of NI formation in stented allograft.
A: The NI area of the allograft at the site of stent implantation,
anastomoses, and the adjacent non-stented allograft body segment,
n=12, *p,0.05). B: Low level of proliferation in the non-stented body
of the allograft and stented allograft segments. Proliferation at the
anastomoses was higher at the non-stented body of the allograft
(n=12, p=0.002) or stented allograft (n=12, p,0.001).
doi:10.1371/journal.pone.0001894.g003
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ACD ultimately leads to failure of cardiac transplants and is
difficult to manage due to its relative refractoriness to immune
modulation and/or a variety of revascularization procedures,
including percutaneous coronary stent insertion. Distinct from
plaque rupture in atherosclerotic native coronaries, progressive NI
accumulation is the ultimate cause of ACD as well as allograft
ISR[1]. In order to improve our understanding and treatment of
ACD and allograft ISR, we developed a novel sex-mismatched
rabbit model of carotid artery grafting in order to quantitatively
study the contribution of host vs. donor cells during NI formation.
Using both in situ hybridization for the Y chromosome and Q-
PCR for the Y chromosome on NI tissue isolated with the aid of
LCM we show that host derived cells play a dominant role in the
genesis of allograft NI formation. Specifically, 5 weeks after
allografting 72.1% of allograft NI cells are of host origin.
Moreover, when a stent is implanted in a 3 week old allograft
and the resulting NI is examined 2 weeks later we note that 81.5%
of the allograft stent NI cells are host derived.
While a number of human studies unquestionably demonstrate
the presence of host derived cells in allograft NI formation[12–17],
considerable debate lingers in the experimental literature regard-
ing this phenomenon. In part, it can be argued that the
experimental models are poor mimics of the human condition,
and while undoubtedly true, this sweeping statement does not do
justice to the plethora of excellent experimental studies in this field.
Space does not permit a balanced discussion of all of these studies,
hence interested readers are referred to two excellent reviews by
Hillebrands et al.[10,23].
In the current study we used two techniques to detect the Y
chromosome: FISH on arterial cross sections and Q-PCR on
sections of NI carefully isolated with LCM. While the sensitivity of
FISH for the Y chromosome is widely recognized to have limited
sensitivity (e.g., varying between approximately 20–50%) [17,21]
this technique is useful for localization reasons. Quite the opposite,
Q-PCR is exquisitely sensitive for quantifying the percentage of
male tissue in chimeric systems using Y chromosome specific
amplicons (e.g., Y chromosome detection thresholds as low as
0.125%–equivalent to 6 copies of the Y chromosome) [24–27]. We
Figure 4. A–C: FISH hybridization with an SRY specific probe in the NI of a female-to-male allograft with or without stent. Blue areas
show DAPI staining of nuclei with green labeling of Y chromosomes (highlighted with red arrows). The yellow color is due to auto fluorescence of
elastic fibers. Male cells (recipient origin) were detected in NI of female donor allograft without (A) or with stent (B). Male native carotid artery medial
cells are SRY positive (C) and were used as positive controls. D: Arcturus HistoGene stained allograft arterial wall before and after NI microdissected by
LCM. NI=neointima. E: Sample Q-PCR standard curve for GAPDH. F: Percent contribution of recipient cells to the NI in allograft body, allograft stent,
and native vessels.Bars represent means6SEM.
doi:10.1371/journal.pone.0001894.g004
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PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1894Figure 5. Differentiation of circulatory cells in vitro. A: Rabbit PBMCs maintained in culture for 7 days: DiI-acLDL labeling (red, left panel); GSL I-
B4 labeling (green, middle panel); Merged image showing both DiI-acLDL uptake and GSL I-B4 labeling in individual cells (yellow, right panel). B:
Rabbit PBMCs after 28 days in culture: DiI-acLDL labeling is absent (red, left panel), a-SMA expression is evident (green, middle panel), and some cells
that do not express a-SMA express the macrophage marker, RAM-11 (red, right panel). For both A and B: blue DAPI nuclear counterstain and 6400
magnification.
doi:10.1371/journal.pone.0001894.g005
Figure 6. Differentiation of circulatory cells in vivo. A: PBMCs labeled in vitro with PKH26 dye (red) and DAPI nuclear counterstain (blue);
magnification:61000. These cells were injected into the carotid artery immediately after stent insertion. B: Cross section of native rabbit carotid artery
14 days post stent implantation (H&E stain,). C: PKH26-labelled PBMCs (red) were detected in the NI of stented artery. D: Some PKH26-labelled PBMCs
(red) were also immunopositive for a-SMA (green). For panels B–D: arrows or autofluorescence delineate the internal elastic lamina; *denote sites of
manually removed stent struts; magnification: 6400.
doi:10.1371/journal.pone.0001894.g006
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previous study whereby the investigators limited their cell sampling
protocol to cells that were a-SMA immunopositive and derived
their conclusions from the analyses of only 21 nuclei harvested
from 3 allografts[28]. In contrast, we performed LCM on a total of
12 allografts (6 male to female, and 6 female to male), with analyses
performed at 2 specific subsegments within each graft (i.e., unstented
body of graft, and stented mid-segment). As well, using Q-PCR
protocol with remarkable linearity for the amplification reaction, we
do not rely simply on the presence or absence of an amplicon. Thus,
while we acknowledge the pioneering work by other investigators in
this field, particularly Hillebrands and colleagues, our work expands
upon the initial studies and provides a large data set to draw
quantitative conclusions from.
Undoubtedly, the NI of the allografts in our study is the result of
both the response to stent implantation and the alloimmune
features of vasculopathy; however, this is no different from the
cardiac transplant recipient with ACD who undergoes coronary
stenting. Stenting ultimately results in increased NI formation that
cannot be explained by excessive proliferation. Actually, the
proliferation rates in stented or non-stented allografts were
similarly low and comparable to that of the stented native
arteries–observations that are consistent with our previous study of
the response to stent implantation in rabbits[18].
To further demonstrate that rabbit circulatory cells can
populate and differentiate into vascular cells within the NI of
stents we performed two additional experiments. First, we
demonstrated that PBMCs from rabbits can differentiate in vitro
and at day 7 express markers consistent with an endothelial lineage
(DiI-acLDL uptake, GSL I-B4 labeling). By 4 weeks in vitro the
same cells no longer express these endothelial cell markers, but
instead showed features consistent with either SMCs or macro-
phages (e.g., immunolabeled for a-SMA or RAM-11; respectively).
Second, when PBMCs are tagged with the fluorescent PKH26 dye
and injected at time of native carotid artery stent insertion, they
constitute a surprisingly high percentage (9%) of the stent NI cell
population 14 days later.
Perhaps the most intriguing observation from the current study
is the detection of cells that express the endothelial lineage marker
GSL I-B4[19,20] within the NI of both non-stented and stented
allograft segments, as well as stented native arteries. In situ, these
cells are morphologically similar to NI SMCs, as they are
surrounded by an extracellular matrix and do not appear to be
part of an organized vasa vasorum. Certainly, in the porcine
model of stent neointimal formation, SMCs almost exclusively
populate the neointima, thereby raising the possibility that these
GSL I-B4 cells may be unique to the rabbit model[29]. While the
involvement of cells expressing other endothelial markers in
experimental lesions formation is not novel [30,31] to our
knowledge, this is the first report of GSL I-B4 positive cells within
the NI of stented arteries. Given our current data as well as that
from other laboratories[32–34] showing the differentiation of
PBMCs to either endothelial cells, SMCs or macrophage
phenotypes, it is tempting to speculate that GSL I-B4 positive
NI cells are a form of circulatory progenitor cells that later
differentiates in vivo into a SMC or macrophage phenotype. It is
less likely that these cells eventually constitute vasa vasorum within
the stent NI because although neovascularization of atheroscle-
rotic lesions is common, vasa vasorum are exceedingly rare in ISR
lesions[35].
Finally, there are limitations to our studies. First, it must be
remembered that we detected host-derived NI cells at a relatively
early interval in lesion development and it is unclear if these host-
derived cells survive and participate in mature lesion formation.
While Religa and colleagues [36] noted a similar frequency of
host-derived SMCs in 8 week old allografts, Bentzon and
colleagues [37] found only locally derived cells at 20 and 32 week
old after allografting. Hence, it is possible that the early
engraftment of host-derived cells (perhaps facilitated by apoptosis
of local vessel wall cells) is later replaced by a regrowth of local cells
that are stimulated by immune-mediated inflammation. A second
question relates to the prospect that host cells from the native
carotid artery anastomoses migrated inward to colonize the
allografts. Our rabbit model used isotransplanted carotid segments
that are quite long (30 mm). Given that each stent was 12 mm
long and placed in the middle of the allograft, vascular cells from
the adjacent native carotid artery would have to migrate at least
9 mm in a period of two weeks to reach the margins of the stent. It
is unlikely that two weeks is sufficient time for inward migration of
cells from the anastomoses to populate the stent NI. Moreover, in
our study the NI of the allograft body between either anastomosis
and the stent is approximately 50% smaller than that of the stent
itself. Therefore, if inward migration of mature carotid artery cells
contributed to stent NI formation, it is surprising to note that the
intervening allograft body shows a ‘‘gap’’ in the NI area relative to
that of the more centrally located stented segment. Third, the
engraftment of ex vivo PKH26-labeled cells into the stent NI was
remarkably high, and perhaps reflects modifications of these cells
that occurred while in culture (e.g., upregulated expression of
integrins). Hence, we must cautiously interpret the magnitude of
this observation, yet can acknowledge that this information is
supportive of the concept that blood derived cells can directly
participate in stent NI formation. Finally, one must ask why were
all of the NI cells not blood borne? Perhaps one clue might come
from elegant studies performed decades ago that clearly
demonstrated the role of tissue wall hypoxia in the genesis of the
NI. Essentially, the vasa vasorum of carotid arteries arise from
terminal branches of adjacent arteries (e.g., ophthalmic)[38].
Hence, the harvesting of these arterial allografts ultimately results
in disruption of the vasa vasorum and leads to vessel wall hypoxia–
a phenomenon previously shown to induce atherosclerotic
lesions[39]. Therefore, it begs the question could this hypoxic
stimulus be a confounding factor that prompts NI expansion by
endogenous SMCs that, in effective, partially minimize the
involvement of blood borne (circulatory) cells?
In summary, our sex-mismatched carotid allograft rabbit model
provides a novel method to study NI formation in ACD and the
response stent implantation in allografts. Our findings suggest that
blood-borne, host-derived progenitor cells–including cells of
endothelial lineage–are important contributors to NI formation
in both these lesions. Hence, modulating the mobilization,
homing, and differentiation of host derived circulating cells may
provide a new therapeutic target in prevention of ACD and stent
NI formation in allografts.
Materials and Methods
A detailed description of the methodology (Materials and
Methods S1) is provided as supporting information.
Sex-Mismatched Carotid Allograft Model
Animal procedures were carried out with the approval of the
University of Ottawa Animal Care Committee and followed the
guidelines of the Canadian Council on Animal Care. Carotid
artery transplantations were performed between gender-mis-
matched NZW rabbit siblings (2.5–3.0 kg, Charles River
Laboratories, Quebec). Six male and six female rabbits were
recipients of sex-mismatched carotid allografts. Beginning one
Allograft Stent Neointima
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cholesterol diet (Harlan Teklad, Madison, WI) that was continued
till euthanasia. Under general anesthesia, the donor carotid
arterial segment (2.5–3.0 cm long) was harvested and the donor
allowed to recover for subsequent transplantation or euthanized if
donating a second carotid artery. The recipient rabbit was
heparinized (175 IU/kg), the right carotid artery exposed, cross-
clamped over a 3–3.5 cm segment and incised longitudinally. The
harvested donor carotid arterial allograft was anastomosed to the
segment end-to-side with interrupted 8-0 prolene sutures.
Circulation was restored and vigorous pulsations in the
allografted carotid artery without leaking confirmed successful
transplantation. Recipients were then allowed to recover for three
weeks before a cobalt chromium stent (S670, 3.0612 mm,
Medtronic AVE, Inc., Santa Rosa, CA) was deployed at 6
atmospheres in the middle of the allograft (experimental). As well,
a second (control) stent was deployed in the contra-lateral native
carotid artery. Immunohistochemistry was performed on tissue
sections in order to detect the presence of macrophages, SMCs, T
cells, cells of endothelial lineage (GSL I-B4 immunopositive), as
well as proliferating cells. FISH was performed with a specific
probe for the Y chromosome (SRY). LCM intimal tissue was
collected, genomic DNA was isolated and subjected to Q-PCR for
SRY and GAPDH genes in order to asses Y chromosome copy
number relative to that of an autosomal gene, and therefore,
determine the percentage of host or donor cells involved in NI
formation.
Differentiation of PBMCs in vitro and in vivo
Differentiation of rabbit PBMCs was examined in vitro using
previously described methodologies[40]. To track the in vivo fate of
circulatory cells, 1.75610
7 of the rabbit’s own PKH26 labeled
PBMCs (Sigma)[41–43] were selectively re-infused into each
carotid artery immediately post-stent insertion. One S670 stent
was deployed per native carotid artery and 14 days later the
rabbits were euthanized and the stented arteries (n=8) were
harvested. The maximum percentage of PKH26 labeled cells per
HPF was determined.
Supporting Information
Movie S1 Angiogram of stented carotid allograft
Found at: doi:10.1371/journal.pone.0001894.s001 (2.42 MB
MPG)
Movie S2 Angiogram of stented native carotid artery
Found at: doi:10.1371/journal.pone.0001894.s002 (2.00 MB
MPG)
Materials and Methods S1
Found at: doi:10.1371/journal.pone.0001894.s003 (0.07 MB
DOC)
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